Insider Selling: Tempus AI, Inc. (NASDAQ:TEM) COO Sells 20,000 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM) COO Ryan Fukushima sold 20,000 shares of the business’s stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $51.15, for a total transaction of $1,023,000.00. Following the sale, the chief operating officer now owns 924,460 shares of the company’s stock, valued at approximately $47,286,129. The trade was a 2.12 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Ryan Fukushima also recently made the following trade(s):

• On Wednesday, February 19th, Ryan Fukushima sold 2,868 shares of Tempus AI stock. The shares were sold at an average price of $81.87, for a total transaction of $234,803.16.
• On Tuesday, February 4th, Ryan Fukushima sold 20,000 shares of Tempus AI stock. The shares were sold at an average price of $62.50, for a total transaction of $1,250,000.00.
• On Tuesday, January 7th, Ryan Fukushima sold 20,000 shares of Tempus AI stock. The shares were sold at an average price of $39.61, for a total transaction of $792,200.00.
• On Monday, December 16th, Ryan Fukushima sold 3,500 shares of Tempus AI stock. The shares were sold at an average price of $40.23, for a total transaction of $140,805.00.
• On Wednesday, December 11th, Ryan Fukushima sold 120,000 shares of Tempus AI stock. The shares were sold at an average price of $42.51, for a total transaction of $5,101,200.00.

Tempus AI Trading Up 0.5 %

NASDAQ TEM opened at $49.10 on Friday. The stock’s 50-day moving average price is $54.02 and its two-hundred day moving average price is $52.54. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69. Tempus AI, Inc. has a 1 year low of $22.89 and a 1 year high of $91.45.

Institutional Trading of Tempus AI

Institutional investors and hedge funds have recently bought and sold shares of the stock. First Horizon Advisors Inc. acquired a new position in shares of Tempus AI in the 3rd quarter valued at about $30,000. Operose Advisors LLC bought a new stake in Tempus AI during the fourth quarter worth approximately $25,000. Farther Finance Advisors LLC bought a new stake in shares of Tempus AI in the fourth quarter valued at approximately $34,000. Prestige Wealth Management Group LLC boosted its position in shares of Tempus AI by 910.4% in the fourth quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company’s stock valued at $36,000 after acquiring an additional 965 shares during the period. Finally, NewEdge Advisors LLC bought a new stake in shares of Tempus AI in the fourth quarter valued at approximately $49,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. Wolfe Research downgraded shares of Tempus AI from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 26th. Bank of America upped their price objective on shares of Tempus AI from $54.00 to $60.00 and gave the stock a “neutral” rating in a report on Monday, March 3rd. Guggenheim reissued a “buy” rating on shares of Tempus AI in a report on Tuesday, February 25th. Needham & Company LLC upped their price target on shares of Tempus AI from $56.00 to $70.00 and gave the company a “buy” rating in a report on Tuesday, February 25th. Finally, Stifel Nicolaus downgraded shares of Tempus AI from a “buy” rating to a “hold” rating and upped their price target for the company from $45.00 to $65.00 in a report on Monday, November 11th. Six research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $61.18.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.